Targeted Chemo-Photothermal Treatments of Rheumatoid Arthritis Using Gold Half-Shell Multifunctional Nanoparticles
Source abstract
Abstract
We have developed RGD-attached gold (Au) half-shell nanoparticles containing methotrexate (MTX) for the treatment of rheumatoid arthritis (RA), where MTX is the most widely used disease-modifying anti-rheumatic drug (DMARD) for the treatment of RA, and RGD peptide is a targeting moiety for inflammation. Upon near-infrared (NIR) irradiation, heat is locally generated due to Au half-shells, and the drug release rate is enhanced, delivering heat and drug to the inflamed joints simultaneously. RA is a chronic inflammatory disease characterized by synovial inflammation in multiple joints within the penetration depth of NIR light. When combined with NIR irradiation, these nanoparticles containing a much smaller dosage of MTX (1/930 of MTX solution) showed greater therapeutic effects than that of a conventional treatment with MTX solution in collagen-induced arthritic mice. This novel drug delivery system is a good way to maximize therapeutic efficacy and minimize dosage-related MTX side effects in the treatment of RA. Furthermore, these multifunctional nanoparticles could be applied to other DMARDs for RA or other inflammatory diseases.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immunotherapy and Immune Responses · Monoclonal and Polyclonal Antibodies Research · Systemic Lupus Erythematosus Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Nanomedical Graduate Program, Yonsei University, Seoul 120-749, Korea
Division of Rheumatology, Department of Internal Medicine, Institute for Immunology and Immunological Disease, Yonsei University College of Medicine, Seoul 120-752, Korea
Department of Pathology, Yonsei University College of Medicine, Seoul 120-752, Korea
Department of Physics, Yonsei University, Seoul 120-749, Korea
References (23)
Show source-provided references
1. Loo C. · Nano Lett. · 2005 · 5 · 70910.1021/nl050127s ↗
2. Hirsch L. R. · Proc. Natl. Acad. Sci. U.S.A. · 2003 · 100 · 1354910.1073/pnas.2232479100 ↗
3. Huang X. · J. Am. Chem. Soc. · 2006 · 128 · 211510.1021/ja057254a ↗
4. Hauck T. S. · Adv. Mater. · 2008 · 20 · 383210.1002/adma.200800921 ↗
5. Kam N. W. S. · Proc. Natl. Acad. Sci. U.S.A. · 2005 · 102 · 1160010.1073/pnas.0502680102 ↗
6. Moon H. K. · ACS Nano · 2009 · 3 · 70710.1021/nn800852n ↗
7. Park H. · Small · 2008 · 4 · 19210.1002/smll.200700807 ↗
8. Park H. · ACS Nano · 2009 · 3 · 291910.1021/nn900215k ↗
9. Lee S. M. · Adv. Mater. · 2010 · 22 · 404910.1002/adma.201001040 ↗
10. Lee S. M. · Angew. Chem., Int. Ed. · 2011 · 50 · 758110.1002/anie.201101783 ↗
11. Levick J. R. · Arthritis Rheum. · 1981 · 24 · 155010.1002/art.1780241215 ↗
12. Firestein G. S. · Nature · 2003 · 423 · 35610.1038/nature01661 ↗
13. Pincus T. · Arthritis Rheum. · 1984 · 27 · 86410.1002/art.1780270805 ↗
14. Saag K. G. · Arthritis Rheum. · 2008 · 59 · 76210.1002/art.23721 ↗
15. Smolen J. S. · Ann. Rheum. Dis. · 2010 · 69 · 96410.1136/ard.2009.126532 ↗
16. Schnabel A. · Semin. Arthritis Rheum. · 1994 · 23 · 31010.1016/0049-0172(94)90027-2 ↗
17. van Ede A. E. · Semin. Arthritis Rheum. · 1998 · 27 · 27710.1016/S0049-0172(98)80049-8 ↗
18. Hynes R. O. · Nat. Med. · 2002 · 8 · 91810.1038/nm0902-918 ↗
19. Johnson E. A. · Arthritis Rheum. · 1993 · 36 · 13710.1002/art.1780360203 ↗
20. Walsh D. A. · Am. J. Pathol. · 1998 · 152 · 691
21. Zolnik B. S. · J. Controlled Release · 2006 · 112 · 29310.1016/j.jconrel.2006.02.015 ↗
22. Camps M. · Nat. Med. · 2005 · 11 · 93610.1038/nm1284 ↗
23. Lee S. W. · Ann. Rheum. Dis. · 2009 · 68 · 176110.1136/ard.2008.097709 ↗